Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...
Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.